{"id":60320,"date":"2019-02-28T12:38:48","date_gmt":"2019-02-28T12:38:48","guid":{"rendered":"https:\/\/lmcca.wpengine.com\/?p=60320"},"modified":"2019-02-28T12:38:48","modified_gmt":"2019-02-28T12:38:48","slug":"research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia","status":"publish","type":"post","link":"https:\/\/www.lmc.ca\/it\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/","title":{"rendered":"RESEARCH SPOTLIGHT: La combinazione di insulina glargine\/lixisenatide a rapporto fisso migliora la variabilit\u00e0 e il controllo glicemico senza aumentare l'ipoglicemia"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243;][et_pb_row][et_pb_column type=&#8221;4_4&#8243;][et_pb_text _builder_version=&#8221;3.19.14&#8243;]<\/p>\n<h3 align=\"LEFT\">LMC Manna Research\u2019s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide &amp; lantus combination) over the past decade.<\/h3>\n<p>\u00a0<\/p>\n<h3 align=\"LEFT\">This publication is a post-hoc analysis of the data accumulated in the two phase 3 LixiLan trials to explore whether patients benefitted from improved glycemic variability in using the combination LixiLan product. See our abstract below for further information on this latest publication.<\/h3>\n<p>\u00a0<\/p>\n<h3 align=\"LEFT\"><strong>Abstract<\/strong><br \/>Maintaining optimal glycaemic control reduces the risk of micro- and macrovascular complications in patients with type 2 diabetes. Typically, glycaemic control is based on glycated haemoglobin (HbA1c) as a measure of mean glucose concentration; however, this marker does not accurately reflect glycaemic variability (GV), which is characterized by the amplitude, frequency and duration of hypo- and hyperglycaemic fluctuations. In the present study, we analysed data from the LixiLan-O trial, which compared iGlarLixi, a titratable fixed-ratio combination of the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi) and long-acting basal insulin glargine 100 units\/mL (iGlar), with its individual components, and the LixiLan-L trial, which compared iGlarLixi with iGlar. The GV features that were measured were mean and SD of self-measured plasma glucose (SMPG), high blood glucose index (HBGI) and low blood glucose index, area under the SMPG curve for each patient (AUCn), mean absolute glucose (MAG) and mean amplitude of glycaemic excursions (MAGE). By week 30, iGlarLixi improved all GV markers from baseline, with no increased hypoglycaemia risk. Significant improvements were observed in SMPG, SD of SMPG, HBGI, AUCn, MAG and MAGE compared with iGlar, and in SMPG, HBGI and AUCn, compared with Lixi.<\/h3>\n<p>\u00a0<\/p>\n<h3>For the full article, click\u00a0<a href=\"http:\/\/lmcmannaresearch.com\/wp-content\/uploads\/2019\/02\/Aronson-et-al.-LixiLan-Improves-Gycemic-Variability.-DOM-2019.pdf\">HERE.<\/a><\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p><div class=\"et_pb_row et_pb_row_0 et_pb_row_empty\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div> LMC Manna Research\u2019s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide &amp; lantus combination) over the past decade.\u00a0This publication is a post-hoc analysis of the data accumulated in the two phase 3 LixiLan trials to explore whether patients benefitted from improved [&hellip;]<\/p>\n","protected":false},"author":25,"featured_media":60321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","two_page_speed":[],"footnotes":""},"categories":[163,196],"tags":[250,126,104,83,249],"class_list":["post-60320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-publications","tag-canadian-research","tag-clinical-research","tag-diabetes","tag-diabetes-research","tag-lmc-manna-research"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lmc.ca\/it\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes\" \/>\n<meta property=\"og:description\" content=\"LMC Manna Research\u2019s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide &amp; lantus combination) over the past decade.\u00a0This publication is a post-hoc analysis of the data accumulated in the two phase 3 LixiLan trials to explore whether patients benefitted from improved [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lmc.ca\/it\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"LMC Healthcare: Helping You Understand and Control your Diabetes\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LMCDiabetesandEndocrinology\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-28T12:38:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1043\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LMC Healthcare\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lmc_diabetes\" \/>\n<meta name=\"twitter:site\" content=\"@lmc_diabetes\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LMC Healthcare\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/\"},\"author\":{\"name\":\"LMC Healthcare\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\"},\"headline\":\"RESEARCH SPOTLIGHT: Insulin glargine\\\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia\",\"datePublished\":\"2019-02-28T12:38:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/\"},\"wordCount\":315,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/Capture-1.png\",\"keywords\":[\"canadian research\",\"clinical research\",\"diabetes\",\"diabetes research\",\"lmc manna research\"],\"articleSection\":[\"News\",\"Publications\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/\",\"name\":\"RESEARCH SPOTLIGHT: Insulin glargine\\\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/Capture-1.png\",\"datePublished\":\"2019-02-28T12:38:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/Capture-1.png\",\"contentUrl\":\"https:\\\/\\\/www.lmc.ca\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/Capture-1.png\",\"width\":1043,\"height\":410},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/news\\\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.lmc.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RESEARCH SPOTLIGHT: Insulin glargine\\\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.lmc.ca\\\/\",\"name\":\"LMC Healthcare: Helping You Understand and Control your Diabetes\",\"description\":\"Consulting Design Engineers\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.lmc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.lmc.ca\\\/#\\\/schema\\\/person\\\/0d459c76f19eec906969bebe87612783\",\"name\":\"LMC Healthcare\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g\",\"caption\":\"LMC Healthcare\"},\"url\":\"https:\\\/\\\/www.lmc.ca\\\/it\\\/author\\\/andrea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lmc.ca\/it\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/","og_locale":"it_IT","og_type":"article","og_title":"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes","og_description":"LMC Manna Research\u2019s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide &amp; lantus combination) over the past decade.\u00a0This publication is a post-hoc analysis of the data accumulated in the two phase 3 LixiLan trials to explore whether patients benefitted from improved [&hellip;]","og_url":"https:\/\/www.lmc.ca\/it\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/","og_site_name":"LMC Healthcare: Helping You Understand and Control your Diabetes","article_publisher":"https:\/\/www.facebook.com\/LMCDiabetesandEndocrinology\/","article_published_time":"2019-02-28T12:38:48+00:00","og_image":[{"width":1043,"height":410,"url":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png","type":"image\/png"}],"author":"LMC Healthcare","twitter_card":"summary_large_image","twitter_creator":"@lmc_diabetes","twitter_site":"@lmc_diabetes","twitter_misc":{"Written by":"LMC Healthcare","Est. reading time":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#article","isPartOf":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/"},"author":{"name":"LMC Healthcare","@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783"},"headline":"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia","datePublished":"2019-02-28T12:38:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/"},"wordCount":315,"commentCount":0,"image":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png","keywords":["canadian research","clinical research","diabetes","diabetes research","lmc manna research"],"articleSection":["News","Publications"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/","url":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/","name":"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia - LMC Healthcare: Helping You Understand and Control your Diabetes","isPartOf":{"@id":"https:\/\/www.lmc.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#primaryimage"},"image":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png","datePublished":"2019-02-28T12:38:48+00:00","author":{"@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783"},"breadcrumb":{"@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#primaryimage","url":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png","contentUrl":"https:\/\/www.lmc.ca\/wp-content\/uploads\/2019\/02\/Capture-1.png","width":1043,"height":410},{"@type":"BreadcrumbList","@id":"https:\/\/www.lmc.ca\/news\/research-spotlight-insulin-glargine-lixisenatide-fixed-ratio-combination-improves-glycaemic-variability-and-control-without-increasing-hypoglycaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lmc.ca\/"},{"@type":"ListItem","position":2,"name":"RESEARCH SPOTLIGHT: Insulin glargine\/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia"}]},{"@type":"WebSite","@id":"https:\/\/www.lmc.ca\/#website","url":"https:\/\/www.lmc.ca\/","name":"LMC Healthcare: Helping You Understand and Control your Diabetes","description":"Ingegneri Progettisti Consulenti","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lmc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/www.lmc.ca\/#\/schema\/person\/0d459c76f19eec906969bebe87612783","name":"Assistenza sanitaria LMC","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/831e22d0d516971177882663c91de9cbcda2f3a549f3a2d9f98d385139c6e8f2?s=96&d=mm&r=g","caption":"LMC Healthcare"},"url":"https:\/\/www.lmc.ca\/it\/author\/andrea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/posts\/60320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/comments?post=60320"}],"version-history":[{"count":0,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/posts\/60320\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/media\/60321"}],"wp:attachment":[{"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/media?parent=60320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/categories?post=60320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lmc.ca\/it\/wp-json\/wp\/v2\/tags?post=60320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}